ERMES: Evaluation of RadioMitigative Efficacy and Safety of BP-C2
Award Notice Posted
- Solicitation number
- HHS-NIH-NIAID-BAA2019-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Meabco Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93020C00004 Federal contract award
- NAICS code
- Not on record
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
About this opportunity
MEABCO INC. was awarded a fixed price contract by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to evaluate the radio mitigative efficacy and safety of compound BP-C2 through the ERMES program for $5,862,472. The contract requires MEABCO INC. to assess the ability of BP-C2 to mitigate the effects of radiation exposure and ensure its safe use, with work to be completed by February 2, 2021.
Notice text
Awarded contract 75N93020C00004 to MEABCO INC. for 5862472.00 on 2020-04-30.
Notice history
| Notice | Type | Posted |
|---|---|---|
| HHS-NIH-NIAID-BAA2019-1: Research Area 003, Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | Award Notice | |
| HHS-NIH-NIAID-BAA2019-1: Research Area 003, Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | Award Notice | |
| HHS-NIH-NIAID-BAA2019-1: Research Area 002, Development of Therapeutic Products for Antibiotic Resistant Bacteria | Award Notice | |
| This notice | Award Notice | |
| 2019 NIAID Omnibus Broad Agency Announcement | Pre-Solicitation | |
| 2019 NIAID Omnibus Broad Agency Announcement | Special Notice |
6 of 11 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity